EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Ryan C. Ungaro  ¹     Laurent Peyrin-Biroulet  ²     Jean-Frédéric Colombel     Edouard J. Louis  ³     Marc Ferrante  ⁴     Takayuki Matsumoto  ⁵     Chirag Doshi  ⁶     Ana Paula Machado De Lacerda     Valencia Remple     Elena Dubcenco     Samuel Anyanwu     Andrew Garrison     Remo Panaccione  ^7    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² University Hospital of Nancy, Lorraine University, Vandoeuvre, France
³ University Hospital CHU of Liège, Liège, Belgium
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ Iwate Medical University, Morioka, Japan
⁶ AbbVie Inc., North Chicago, United States
⁷ University of Calgary, Calgary, Canada

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)